GlassScriptXen Glaucoma Treatment System
Payments companies reported to CMS as associated with Xen Glaucoma Treatment System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xen Glaucoma Treatment System, per program year, as reported to CMS.
Who makes it
- Abbvie INC. $2.1M associated with Xen Glaucoma Treatment System (2023-2025)
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xen Glaucoma Treatment System
These are the largest totals companies reported as associated with Xen Glaucoma Treatment System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Davinder Grover | Dallas, TX | Ophthalmology | $146,638.23 |
| Arsham Sheybani | Saint Louis, MO | Glaucoma Specialist | $101,532.45 |
| Robert Noecker | Pittsburgh, PA | $95,981.57 | |
| Peter Chang | Houston, TX | Ophthalmology | $80,452.11 |
| Manjool Shah | Ann Arbor, MI | Ophthalmology | $65,890.64 |
| Joseph Panarelli | New York, NY | Ophthalmology | $53,478.45 |
| Shivani Kamat | Dallas, TX | Glaucoma Specialist | $43,441.43 |
| Kingsley Okafor | Denver, CO | Ophthalmology | $36,987.56 |
| Lorraine Provencher | Omaha, NE | Ophthalmology | $36,782.67 |
| Billy Pan | Beverly Hills, CA | Glaucoma Specialist | $34,415.48 |
Prescribed Xen Glaucoma Treatment System?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.